Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 Inhibitor + Gemcitabine/Cisplatin in Advanced BTC
NCT03311789Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2017
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, camrelizumab in biliary tract cancer (BTC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
nivolumabcamrelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03311789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311789.